- Home
- MGN vs NOTV Comparison
MGN vs NOTV Comparison
Compare MGN & NOTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGN
- NOTV
- Stock Information
- Founded
- MGN 2020
- NOTV 1974
- Country
- MGN Malaysia
- NOTV United States
- Employees
- MGN N/A
- NOTV N/A
- Industry
- MGN
- NOTV Biotechnology: Pharmaceutical Preparations
- Sector
- MGN
- NOTV Health Care
- Exchange
- MGN Nasdaq
- NOTV Nasdaq
- Market Cap
- MGN 43.0M
- NOTV 46.7M
- IPO Year
- MGN 2025
- NOTV 1997
- Fundamental
- Price
- MGN $1.50
- NOTV $1.03
- Analyst Decision
- MGN
- NOTV Strong Buy
- Analyst Count
- MGN 0
- NOTV 1
- Target Price
- MGN N/A
- NOTV $5.00
- AVG Volume (30 Days)
- MGN 637.0K
- NOTV 410.9K
- Earning Date
- MGN 11-28-2025
- NOTV 12-02-2025
- Dividend Yield
- MGN N/A
- NOTV N/A
- EPS Growth
- MGN N/A
- NOTV N/A
- EPS
- MGN 0.07
- NOTV N/A
- Revenue
- MGN $13,484,571.00
- NOTV $505,299,000.00
- Revenue This Year
- MGN N/A
- NOTV $5.64
- Revenue Next Year
- MGN N/A
- NOTV $5.16
- P/E Ratio
- MGN $21.59
- NOTV N/A
- Revenue Growth
- MGN N/A
- NOTV 0.85
- 52 Week Low
- MGN $1.30
- NOTV $1.00
- 52 Week High
- MGN $8.63
- NOTV $6.48
- Technical
- Relative Strength Index (RSI)
- MGN N/A
- NOTV 29.51
- Support Level
- MGN N/A
- NOTV $1.03
- Resistance Level
- MGN N/A
- NOTV $1.17
- Average True Range (ATR)
- MGN 0.00
- NOTV 0.11
- MACD
- MGN 0.00
- NOTV -0.02
- Stochastic Oscillator
- MGN 0.00
- NOTV 5.79
About MGN Megan Holdings Limited Ordinary Shares
Megan Holdings Ltd is principally engaged in the development, construction and maintenance of aquaculture farms and related works. Its operations are based in Malaysia. The company's operating segments include: Aquaculture and agriculture; Industrial solutions; and Investment in marketable securities. It derives maximum revenue from Aquaculture and agriculture, which involves development, construction, and maintenance of aquaculture and agriculture farms and related works.
About NOTV Inotiv Inc.
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.